Yohei Takumi

Yohei Takumi

Auto-generated profile, based on publicly available information

Yohei Takumi

Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine

Research Focus & Metrics

Representative Publications

View All Publications
14 July 2024 in Chest
Verified
Journal Article
Closed access
Shinkichi TakamoriShinkichi Takamori
Shinkichi Takamori
AOAtsushi Osoegawa
Atsushi Osoegawa
AHAsato Hashinokuchi
Asato Hashinokuchi
TKTakashi Karashima
Takashi Karashima
YTYohei Takumi
Yohei Takumi
TKTakefumi Komiya
Takefumi Komiya

23 November 2022 in Cancer Medicine
Verified
Journal Article
Open access
YTYohei Takumi
Yohei Takumi
SASachiko Arai
Sachiko Arai
CSChiaki Suzuki
Chiaki Suzuki
KFKoji Fukuda
Koji Fukuda
ANAkihiro Nishiyama
Akihiro Nishiyama
SYSeiji Yano
Seiji Yano
Background: Entrectinib is an effective drug for treating solid tumors with NTRK gene rearrangement and non‐small cell lung cancer (NSCLC) with ROS1 gene rearrangement. However, its efficacy is limited by tolerance and acquired resistance, the mechanisms of which are not fully understood. The growth factors produced by the tumor microenvironment, including hepatocyte growth factor (HGF) produced by tumor‐associated fibroblasts, critically affect the sensitivity to targeted drugs.Methods: We investigated whether growth factors that can be produced by the microenvironment affect sensitivity of NTRK1‐rearranged colon cancer KM12SM cells and ROS1‐rearranged NSCLC HCC78 cells to entrectinib both in vitro and in vivo.Results: Among the growth factors assessed, HGF most potently induced entrectinib resistance in KM12SM and HCC78 cells by activating its receptor MET. HGF‐induced entrectinib resistance was reversed by the active‐HGF‐specific macrocyclic peptide HiP‐8 and the MET kinase inhibitor capmatinib in vitro. In addition, HGF‐producing fibroblasts promoted entrectinib resistance in vitro (culture model) and in vivo (subcutaneous tumor model). The use of capmatinib circumvented entrectinib resistance in a subcutaneous tumor model inoculated with KM12SM and HGF‐producing fibroblasts.Conclusion: Our findings suggest that growth factors in the tumor microenvironment, such as HGF, may induce resistance to entrectinib in tumors with NTRK1 or ROS1 rearrangements. Our results further suggest that optimally co‐administering inhibitors of resistance‐inducing growth factors may maximize the therapeutic efficacy of entrectinib.

23 January 2018 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
MKMirei Kamei
Mirei Kamei
YFYutaka Fujitomi
Yutaka Fujitomi
YKYoshiyuki Kondo
Yoshiyuki Kondo
TAToru Adachi
Toru Adachi
KSKohei Shibata
Kohei Shibata
KSKenji Sugio
Kenji Sugio
We herein report a 50-year-old Japanese woman with breast cancer who complained of blurred vision and central scotoma in her left eye on the 12th day after surgery. Subsequently, the sudden-onset binocular visual disorder progressed, and she was diagnosed with cancer-associated retinopathy (CAR) based on the clinical findings. Although her visual acuity temporarily improved following the start of adjuvant chemotherapy, reductions in her visual acuity progressed once again. After two courses of steroid pulse therapy initiated from the 59th day following the onset of CAR, although her visual field was still constricted, her binocular visual acuity improved from finger movement to 0.8 2 months later. The shorter the period from onset to treatment, the better the prognosis of the visual function. However, a diagnosis is often delayed because the incidence of this disease is very rare. Therefore, it is important to suspect CAR whenever a sudden visual disorder develops in cancer patients. Furthermore, treatment is believed to be effective even if steroid therapy is started up to 2 months from onset.

13 August 2018 in Lung Cancer
Verified
Journal Article
Closed access
PDF file
THTakafumi Hashimoto
Takafumi Hashimoto
AOAtsushi Osoegawa
Atsushi Osoegawa
YTYohei Takumi
Yohei Takumi
MAMiyuki Abe
Miyuki Abe
RKRyoji Kobayashi
Ryoji Kobayashi
KSKenji Sugio
Kenji Sugio

16 July 2023 in Thoracic Cancer
Verified
Journal Article
Open access
AOAtsushi Osoegawa
Atsushi Osoegawa
MAMiyuki Abe
Miyuki Abe
YTYohei Takumi
Yohei Takumi
THTakafumi Hashimoto
Takafumi Hashimoto
TKTakashi Karashima
Takashi Karashima
KSKenji Sugio
Kenji Sugio
Background: Several studies have reported that the high expression of programmed death‐ligand 1 (PD‐L1) within tumor cells predicts a poor prognosis. However, the relationship between the PD‐L1 expression and lymph node metastasis or driver mutations in lung cancer remains poorly understood.Methods: A total of 356 consecutive patients who underwent surgical resection for primary lung cancer were included in the study. There were 268 adenocarcinomas including 100 EGFR mutations, 67 squamous cell carcinomas (Sq), and 21 other histologies. The high expression of PD‐L1 was defined as a tumor proportion score (TPS) of ≥50. The relationship between the PD‐L1 expression and clinicopathological factors and recurrence‐free survival (RFS) was analyzed.Results: The PD‐L1 expression was high in 75 patients. It was significantly related to smoking history, Sq histology, driver mutation negative, elevated serum carcinoembryonic antigen levels, and lymph node metastasis. Among patients with driver mutations, a high PD‐L1 TPS was found in patients with EGFR G719X mutation. A significant difference in RFS was observed in adenocarcinoma patients. A multivariate analysis of adenocarcinoma cases revealed that tumor size and lymph node metastasis were independent prognostic factors for poor RFS, while the PD‐L1 expression was not. A logistic regression analysis revealed that the absence of driver mutations, lymph node metastasis, and a history of smoking were significantly associated with the high expression of PD‐L1.Conclusion: Lymph node metastasis was positively related with the high expression of PD‐L1, resulting in poor RFS. A high PD‐L1 TPS was observed in patients with the EGFR G719X mutation.

31 October 2023 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
MAM. Abe
M. Abe
AOAtsushi Osoegawa
Atsushi Osoegawa
TKT. Karashima
T. Karashima
Shinkichi TakamoriShinkichi Takamori
Shinkichi Takamori
YTY. Takumi
Y. Takumi
KSK. Sugio
K. Sugio